Research programme: amyotrophic lateral sclerosis therapy - Sangamo Therapeutics

Drug Profile

Research programme: amyotrophic lateral sclerosis therapy - Sangamo Therapeutics

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sangamo BioSciences
  • Class
  • Mechanism of Action Insulin-like growth factor I stimulants; Nerve growth factor stimulants; Transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 07 Jun 2007 No development reported - Preclinical for Amyotrophic lateral sclerosis in USA (unspecified route)
  • 30 Jul 2004 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top